Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2008

View Archived Issues

Antitumor activity reported for WP-1193 in brain tumor cells

Talampanel safe when added to radiotherapy and temozolomide in glioblastoma patients

Phase II studies show romidepsin monotherapy is active in peripheral and cutaneous T-cell lymphomas

Novavax reports top-line results from phase IIa influenza vaccine trial

Evidence of pharmacodynamic activity seen for triciribine in phase I trial

Clinical data show efficacy for bosutinib in chronic myelogenous leukemia

AEterna Zentaris completes patient recruitment into phase III safety trial of cetrorelix in BPH

Delcath enrolls 50% of patients in metastatic melanoma phase III clinical trial of PHP system

Merck & Co. initiates phase I clinical development of estrogen receptor compound

Synta earns USD 15 million in milestone payments from GSK for development of elesclomol

Theratechnologies reports results from phase III clinical trial of tesamorelin

FibroGen initiates phase I FG-3019 trial in patients with pancreatic cancer

Eldecalcitol reduces incidence of new vertebral fractures in phase III trial

EntreMed focuses resources on development of ENMD-2076

Peplin completes enrollment for its first phase III PEP-005 trial in actinic keratosis

QLT reports interim results of phase II Visudyne combination therapy study

Adlea significantly reduces pain after total knee replacement in phase III trial

Basilea commences U.S. phase III study for alitretinoin in severe hand eczema

New agents for arthritis reported in recent patents

FDA accepts Transcept's Intermezzo NDA for review

Lundbeck initiates phase III trials with desmoteplase in ischemic stroke

Naproxcinod shows robust blood pressure results in phase III pooled analysis

NX-1207 shows significantly less sleep interruption for men with BPH

Recent patents divulge novel analgesic agents

New agents for psychiatric disorders described in recent Lilly and NeuroSearch patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...